Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs
Authors:
- 1 October 2019
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 71 (4) , 666-672
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet NeedsAnnual Review of Medicine, 2017
- Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 TrialGastroenterology, 2016
- Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 InfectionDrugs, 2016
- Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free RegimensGastroenterology, 2016
- The importance of resistance to direct antiviral drugs in HCV infection in clinical practiceJournal of Hepatology, 2016
- Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated CirrhosisNew England Journal of Medicine, 2015
- Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virusHepatology, 2015
- Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 InfectionDrugs, 2015
- Hepatitis C virus drug resistance–associated substitutions: State of the art summaryHepatology, 2015
- EASL Recommendations on Treatment of Hepatitis C 2014Journal of Hepatology, 2014